Big.Rich, yes and a finally some clarity although IMO this is not the way to communicate it, unless of course we are going to receive a PR 'Update'.
1) All chemo+bavi is GONE. Breast, Lung, etc. The only one still mentioned that was about to start is the one with AstraZeneca (all solid cancers but there the good news is that it is under evaluation so it least I think it is fair to say they will not start enrolling that one).
2) The AstraZeneca clinical trials have not been removed but now show what PPHM announced would happen at the Q/CC. That was that AstraZeneca remains on-board and that the trials would be re-evaluated. I hope they get CHEMO out of it. If PPHM+AstraZeneca (Durvalumab+Bavituximab) would have been history these trials would have been removed as they did with the planned NSCLC trial).
3) ALL RECRUITING is stopped now. For Radiation trial (capecitabine) and CTLA-4 (ipilimumab) we may expect some read-outs or results. Liver and Stage IV NSCLC still open so data may be maturing.
IMO we will ONLY see Immuno-Oncology clinical trials start in the near future. If CHEMO is out of the equation then no more need limit the number of solid cancers. Question is how does that work for conditions where CHEMO is still in the SOC. That may be the stick that forces chemo kind of back into the equation.
I hope any announcement of PPHM goes in the direction of this web-site update and that they don't turn completely back to chemo when not needed by clinical trial regulation (including the SOC).
With AstraZeneca carrying the 100% cost of the Immuno-Oncology product (Durvalumab) and given the size of the trials (assuming they don't change them) PPHM will be able to operate low-cost on clinical trials and will, this time, not be alone. And the needed Bavituximab is already available due to stopped SUNRISE maintenance.
Now all we miss is a more official and tying collaboration/partnership then those that we already have.
News 
Market Data 
Discover 
